Implant Production Rate (IPR)
The supply behind implant uptake. The bottleneck on the most valuable surveillance surface.
Formula
Thresholds & Bands
| Band | Range | State |
|---|---|---|
| On-plan | ≥ target | ok |
| Behind | 80-100% target | warn |
| Stalled | < 80% target | crit |
Why This Metric Matters
Implant Production Rate is the hard supply constraint on Halo deployment. Every uptake target, every surveillance expansion plan, and every new-cohort enrollment initiative is ultimately gated by the number of implant units the Manufacturing division can provision per week. Production shortfalls do not merely delay coverage — they create windows during which newly identified subjects remain outside the biometric telemetry mesh, invisible to PANACEA and VITALNET. The Directorate treats sustained production gaps as a Tier-1 operational risk because they compound across downstream metrics.
Threshold Justification
The "On-plan" threshold is defined dynamically against the current quarter's deployment schedule, which PANACEA generates from demographic intake projections and attrition models. The 80% floor for the "Behind" band was established after the 2023 supply crisis demonstrated that production below this level causes uptake pipeline stalls that take 6-8 weeks to clear once resolved.
Historical Context
IPR was formalized as a PANOPTICON metric when the Halo program transitioned from pilot to mass deployment in 2021. Production capacity has scaled from approximately 12,000 units per week to the current target of 85,000, driven by the commissioning of three additional implant fabrication bays. The Q3 2023 rare-earth supply disruption remains the only period in which production fell to "Stalled" status for more than two consecutive weeks.
Collection Method
Production counts are reported directly from the Manufacturing Implant Bay's automated line-tracking system, which logs each unit at the final quality-assurance checkpoint. Shipping confirmation data from Vector Fleet logistics validates that provisioned units have entered the distribution chain. PANACEA reconciles production logs against deployment records weekly to identify inventory discrepancies or diversion.
Known Failure Modes
Quality-assurance rejection batches are sometimes counted as produced before final inspection, temporarily inflating the weekly figure until reconciliation catches the overcount. Supply-chain disruptions in specialized biocompatible substrates can cause sudden production cliff events that are not predicted by the gradual-decline models PANACEA uses for forecasting. Firmware pre-loading failures at the provisioning stage can create units that pass hardware QA but are non-functional at deployment, appearing as production without contributing to uptake.